Oxytocin (Pitocin)

FDA Approved

Neurohypophysial Peptide | Social Bonding & Reproductive Hormone

Weight: 1,007.19 Da
Half-life: 3-6 minutes
Chain: 9 amino acids
3 studies
2024 latest
FDA Approved
Dose Intranasal: 20-24 IU; Injectable: 10-40 IU; Sublingual: 50-100 IU
Frequency As needed for social/sexual support, or 1-2x daily for anxiety/PTSD protocols; max 1 dose per 24hr for sexual function
Cycle As needed for research applications; 4-12 weeks for anxiety/autism protocols
Storage Refrigerate at 2-8°C; protect from light
Accumulation Plotter

Community Research

Join others researching Oxytocin — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Nine-amino-acid peptide hormone produced in hypothalamus, released by posterior pituitary. Functions in social bonding, trust, empathy, reproduction, childbirth, lactation. FDA-approved synthetically for labor induction and postpartum hemorrhage.

Mechanism of Action

Binds oxytocin receptors on uterine smooth muscle, triggering calcium influx and myometrial contractions. Stimulates prostaglandin release. In CNS, modulates GABAergic, serotonergic, dopaminergic neurotransmission; reduces cortisol and HPA axis activity.

01 FDA-approved for labor induction with precise dosing via IV
02 Immediate onset in obstetric settings
03 Established safety profile in clinical use
04 Researched for anxiety, PTSD, autism, sexual dysfunction

Molecular Data

Molecular Weight
1,007.19 Da
Chain Length
9 amino acids
Type
Cyclic nonapeptide
Amino Acid Sequence
One-letter: CYIQNCPLG?
H₂N
C 1
O ‖ C
N
Y 2
O ‖ C
N
I 3
O ‖ C
N
Q 4
O ‖ C
N
N 5
O ‖ C
N
C 6
O ‖ C
N
P 7
O ‖ C
N
L 8
O ‖ C
N
H
G 9
O ‖ C
N
H
? 10
COOH
Cys
1

Cysteine

Position 1

Tyr
2

Tyrosine

Position 2

Ile
3

Isoleucine

Position 3

Gln
4

Glutamine

Position 4

Asn
5

Asparagine

Position 5

Cys
6

Cysteine

Position 6

Pro
7

Proline

Position 7

Leu
8

Leucine

Position 8

Gly
9

Glycine

Position 9

NH2
10

NH2

Position 10

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Obstetric (FDA Approved)
Labor Induction most effective

Initiates or augments uterine contractions when vaginal delivery medically indicated.

Postpartum Hemorrhage Control most effective

Controls postpartum bleeding through uterine contraction stimulation during third stage.

Incomplete Abortion Management effective

Adjunctive therapy for incomplete or inevitable abortion in second trimester.

Research/Emerging
Autism Spectrum Disorders moderate

Extensive research with mixed results on social functioning; optimal dosing unclear.

PTSD Augmentation effective

Combined with exposure therapy; shows reduced PTSD/depression symptoms.

Social Anxiety moderate

Decreases amygdala reactivity to social threats; normalizes brain connectivity.

Sexual Function effective

Improves libido, arousal, orgasm intensity in both sexes.

Dosing Protocols

IV or IM administration in clinical settings. IV provides immediate onset; requires continuous infusion and monitoring for labor use.

GoalDoseFrequencyRoute
Labor Induction0.5-2 mU/min initial, titrate to 1-2 mU/min every 30-60 minContinuous IV infusionIV (diluted)
Postpartum Hemorrhage Prevention10 units IM or 10-40 units in IV solutionSingle dose after placental deliveryIM or IV infusion

Reconstitution Instructions

Materials Needed:
  • Oxytocin injection USP (10 units/mL)
  • Compatible IV solution (0.9% NaCl or Lactated Ringer's)
  • IV infusion pump (required)
  • Continuous fetal monitoring equipment
  1. 1 Hospital/clinical procedure—qualified healthcare professionals only
  2. 2 Dilute oxytocin in compatible IV solution per facility protocol
  3. 3 Typical dilution: 10 units in 1000mL = 10 mU/mL
  4. 4 Use infusion pump for precise rate control
  5. 5 Monitor uterine contractions and fetal heart rate continuously

Interactions

~
Vasopressin (AVP)
Structurally similar; overlapping receptor affinity with potential additive effects.
monitor
++
Selank
Complementary anxiolytic effects—Selank modulates GABA; oxytocin acts on central receptors.
synergistic
++
PT-141 (Bremelanotide)
Complementary sexual function effects via different pathways.
synergistic
++
Kisspeptin
Both involved in reproduction; kisspeptin stimulates GnRH; oxytocin enhances arousal.
synergistic
+
BPC-157
No direct interactions; different mechanisms (tissue repair vs social function).
compatible
~
SSRI Antidepressants
SSRIs may affect endogenous oxytocin; combined use requires healthcare provider oversight.
monitor
!
Alcohol
Alcohol suppresses oxytocin release; reduces therapeutic effects.
avoid

What to Expect

Injectable
IV: 1-3 minute onset, 30-60 minute duration; IM: 3-5 minute onset
Intranasal
15-30 minute onset, peak 30-60 minutes, 2-4 hour duration
Sublingual
30-45 minute onset, peak ~60 minutes, 2-4 hour duration

Side Effects & Safety

Common Side Effects

  • Mild headache
  • Nasal irritation (intranasal)
  • Nausea or vomiting
  • Transient blood pressure changes

Stop Signs - Discontinue if:

  • Uterine hyperstimulation or fetal distress (injectable)
  • Severe or persistent headache
  • Signs of water intoxication (confusion, seizures, swelling)
  • Severe nasal irritation or bleeding
  • Allergic reaction (rash, breathing difficulty)

Contraindications

  • Certain obstetric conditions (see prescribing info)
  • Pregnancy (without medical supervision)
  • Active sinus infection (intranasal)
  • Severe hyponatremia

Quality Checklist

Good Signs

  • FDA-approved pharmaceutical product from licensed pharmacies (injectable)
  • Clear, colorless solution without particles or discoloration
  • Proper packaging with verified lot number, expiration, concentration
  • Licensed compounding pharmacy source with USP compliance

Warning Signs

  • Variable compounding quality between pharmacies
  • Nasal congestion reduces intranasal absorption
  • Sublingual has lower bioavailability than intranasal

Bad Signs

  • Cloudy, discolored, or particulate solution
  • From unlicensed or unverified sources
  • Improper storage or broken cold chain

References

  • Intranasal Oxytocin in Autism Spectrum Disorder
    (2021)

    N=290 children/adolescents; 48 IU daily; 24 weeks. Did not significantly improve social functioning vs placebo; highlights need for better patient selection.

  • Oxytocin Augmented Prolonged Exposure Therapy for PTSD
    (2019)

    Veterans with PTSD; 40 IU intranasal combined with PE therapy. Lower PTSD and depression symptoms; higher therapeutic alliance vs placebo.

  • Intranasal Oxytocin for Obesity
    (2024)

    N=61 adults with obesity; 24 IU four times daily; 8 weeks. No weight loss but significant reduction in caloric intake; improved mental health-related quality of life.

Related Peptides

Selank synergistic

Complementary anxiolytic effects—Selank modulates GABA; oxytocin acts on central receptors.

Kisspeptin synergistic

Both involved in reproduction; kisspeptin stimulates GnRH; oxytocin enhances arousal.

BPC-157 compatible

No direct interactions; different mechanisms (tissue repair vs social function).

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.